Indication: Advanced Solid Tumors
A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Sub-indication: Miscellaneous Malignancies
Study Type: Drug Study
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Sponsor: BioAtla LLC
Learn more at ClinicalTrials.gov
Email for more information: MISC-NCIResearch@nortonhealthcare.org
